

DAY 3

Sunday, February 12, 2023

E : English
 Ⓜ : Simultaneous interpretation is provided
 BF : Breakfast Seminar LS : Luncheon Seminar

	7:30	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00
Nagoya Congress Center	Room 1 (Building 1) 2F Century Hall	8:00~8:50 BF1 Current Status and Prospects of CAR-T Treatment Speaker: Naoki Hosen Chair: Koji Nagafuji (Mitsubishi Medical Affairs, Eisai Sciences K.K.)	9:00~11:00 Symposium 6 Chronic GVHD Yoshihiro Inamoto, Yuki Asano-Mori P.12			11:30~12:20 LS14 T cell qualities and the response to CD19 CAR-T cell immunotherapy Speaker: Cameron J. Turtle Chair: Yoshiyuki Takahashi (Bristol Myers Squibb K.K.)		13:25~13:45 Awards Ceremony	13:50~14:10 JSTCT Prize Commemorative Lecture	14:15~15:00 Plenary Session Plenary Session Shuichi Taniguchi Satoshi Takahashi P.13		15:40~18:00 Public Forum	
	Room 2 (Building 4) 1F Shiratori Hall (North)	8:00~8:50 BF2 Development of Cell Therapy for Acute Lymphocytic Leukemia Speaker: Koji Kato Chair: Kazuhiro Ikegame (Otsuka Pharmaceutical Co., Ltd.)	9:00~10:00 Workshop 3 Propriety of HSCT after CD19-CART therapy Yuhki Koga, Hideki Muramatsu P.13	10:05~11:15 Pro • Con 2 Considering eligibility to HSCT Shingo Yano, Tetsuya Nishida P.14		11:30~12:20 LS15 Isotretinoin: Clinical practice with relapse or refractory Large B cell Lymphoma. Long-term remission. An overview of evolution of genetic trials and real-world clinical experience Speaker: David Miklos Chair: Takanori Teshima (Daiichi Sankyo Co., Ltd. / Eisai Sciences K.K.)							
	Room 3 (Building 4) 1F Shiratori Hall (South)	8:00~8:50 BF3 Treatment Advances in Relapsed/Refractory DLBCL Speaker: Kana Miyazaki Chair: Seitaro Terakura (Symbio Pharmaceuticals Limited)	9:00~10:10 Pro • Con 3 Positioning of CAR-T and auto HSCT in DLBCL treatment Masashi Sawa P.14	10:15~11:15 Workshop 4 Considering HSCT outcome originating from Japan Yasushi Hiramatsu, Masahide Yamamoto P.15		11:30~12:20 LS16 Management of Secondary Immunodeficiencies in blood cancer Speaker: Joshua Richter Chair: Toshihiro Miyamoto (Takeda Pharmaceutical Company Limited)							
	Room 4 (Building 3) 3F International Conference Room	8:00~8:50 BF4 Complication Management After Hematopoietic Stem Cell Transplantation Speaker: Naoyuki Uchida Chair: Ryoji Kobayashi (Japan Medical Office, Eisai Pharmaceutical Company Limited)	9:00~10:00 The allied organizations forum for promoting hematopoietic stem cell transplantation Takanori Teshima P.15			11:30~12:20 LS17 Transplantation for multiple myeloma Speakers: Kotaro Miyao, Kazuhito Suzuki Chair: Tadao Ishida (ONO PHARMACEUTICAL CO., LTD.)							
	Room 5 (Building 1) 4F Reception Hall	8:00~8:50 BF5 Management of Invasive Fungal Infection up to date Speaker: Takehiko Mori Chair: Shuichi Taniguchi (Asahi Kasei Pharma Corporation)	9:00~10:00 Nursing Special Lecture Hisayo Doi Reiko Yamahana P.16	10:05~11:05 Nursing Workshop Considering fertility treatment Rie Tsuruta, Akiko Unesoko P.16		11:30~12:20 LS18 Issues and needs in blood cancer survivors who received allogeneic hematopoietic cell transplantation -What can we do to assist survivors in return to work? Speaker: Sako Kurosawa Chair: Tomoko Yashima (CHUGAI PHARMACEUTICAL CO., LTD.)			14:00~15:00 Brush up on LTFU Nurse Supporting career development of LTFU staff Chieko Indo, Maki Yokota P.16				
	Room 6 (Building 4) 3F 431+432		9:00~10:00 Oral Session 29 Clinical Outcomes: Acute Leukemia II Hisayuki Yokoyama P.56	10:05~11:05 Oral Session 30 Clinical Outcomes: Aplastic Anemia Hirohito Yamazaki P.57		11:30~12:20 LS19 Clinical Outcomes and Background of Kymriah in Relapsed or Refractory DLBCL. Learned from Clinical Experience Speakers: Satoshi Yoshizawa, Nobuharu Fujii Chair: Hirohito Yamazaki (Novartis Pharma K.K.)							
	Room 7 (Building 2) 2F 222 + 223		9:00~10:00 Oral Session 31 Clinical Outcomes: MDS, MPN Hiroya Tamaki P.58	10:05~11:05 Oral Session 32 Dietary and General Management Sung-Won Kim P.60		11:30~12:20 LS20 Risk management for SOS/VOI as team efforts Speakers: Ken-ichi Matsuoka, Yuki Nimobe Chair: Satoshi Takahashi (Nippon Shinyaku Co., Ltd.)							
	Room 8 (Building 2) 2F 224	8:00~8:50 BF6 New treatment strategy for B-ALL in US Speakers: Koji Sasaki Chair: Naoto Takahashi (Amgen K.K. / Astellas pharma inc.)	9:00~10:00 Oral Session 33 Clinical Outcomes: Others III Masuho Saburi P.61	10:05~11:05 Oral Session 34 Transplant Immunity Yoshinobu Maeda P.62		11:30~12:20 LS21 Fungal infections in patients with hematological malignancy: Risk and Pitfall Speaker: Junichiro Yuda Chair: Takahiro Fukuda (Sumitomo Pharma Co., Ltd.)							
	Room 9 (Building 2) 3F 232 + 233		9:00~10:00 Oral Session 35 Stem Cell Harvest and Processing Takafumi Kimura P.63	10:05~10:55 Oral Session 36 BCMA-CAR and Other Immunotherapy Yasuyuki Arai P.64		11:30~12:20 LS22 Impact of Blinatumomab on ALL treatment -from scientific evidence to clinical practice- Speaker: Anthony Stein Chair: Hitoshi Kiyoi (Amgen K.K. / Astellas pharma inc.)	12:30~13:20 Meet the Expert 4 Speaker: Cameron J. Turtle Moderator: Seitaro Terakura P.17						
	Room 10 (Building 2) 3F 234	8:00~8:50 BF7 Future perspective of autologous stem cell transplantation in the era of plerixafor Speaker: Nobuhiro Tsukada Chair: Hideo Harigae (Sanofi K.K.)	9:00~10:00 Oral Session 37 Congenital Disease in Children Masahiro Hirayama P.65	10:05~11:05 Oral Session 38 Rehabilitation III Takahiro Takekiyo P.66		11:30~12:20 LS23 Experience with Response in relapsed/refractory ALL Speaker: Kentaro Fukushima Chair: Koji Kato (Pfizer Japan Inc.)							
	Room 11 (Building 1) 3F 131 + 132		9:00~10:15 Oral Session 39 Post-transplant Relapse and MRD Yasuhiko Shibasaki P.67			11:30~12:20 LS24 Treatment of multiple myeloma and systemic AL amyloidosis - Role of anti-CD138 antibody drug Daratumumab - Speakers: Nobuhiro Tsukada, Yuta Katayama Chair: Kazutaka Sunami (Janssen Pharmaceutical K.K.)	12:30~13:20 Meet the Expert 5 Speaker: Yi Lin Moderator: Reona Sakemura P.17						
	Room 12 (Building 1) 3F 133 + 134		9:00~10:15 Oral Session 40 Infections Chiaki Nakaseko P.68			11:30~12:20 LS25 Management of Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation - Quantitative PCR monitoring for CMV reactivation - Speaker: Katsuo Takenaka Chair: Junichi Sugita (Roche Diagnostics)	12:30~13:20 Meet the Expert 6 Speaker: Georg Stary Moderator: Ken-ichi Matsuoka P.17						
	Room 13 (Building 2) 1F 211		9:00~10:00 Oral Session 41 Viral Infection III Akihisa Sawada P.70			11:30~12:20 LS26 Current and future perspective of hematopoietic stem cell transplantation for B-cell lymphoma Speaker: Makoto Yoshimitsu Chair: Yasushi Miyazaki (Genmab K.K.)							
Poster (Building 1) 1F Event Hall		8:30~12:30 Poster Viewing				12:30~13:20 Poster Presentation	13:20~14:20 Poster Removal						
Exhibition (Building 1) 1F Event Hall		8:30~14:20 Exhibition											

Poster Presentation

- P2-1~P2-8 Post-transplant Relapse, MRD
- P4-1~P4-7 Late Complications III
- P6-1~P6-7 Early Complications II
- P8-1~P8-8 Early Complications III
- P10-1~P10-7 Bacterial Infection
- P12-1~P12-7 Transplant Results: Acute Leukemia II
- P14-1~P14-6 CAR-T: Biomarker/Complications
- P16-1~P16-5 Transplant Results: ML II
- P18-1~P18-5 Fungal Infection
- P20-1~P20-5 Engraftment Failure
- P22-1~P22-4 Viral Infection II
- P24-1~P24-6 Conditioning II
- P26-1~P26-5 cGVHD II
- P28-1~P28-4 Stem Cell Collection
- P30-1~P30-5 Cellular Therapy: Others
- P31-1~P31-5 Transplant Results: Leukemia Others

Nursing Poster Presentation

- NurseP2-1~NurseP2-7 Transplant Nursing II
- NurseP4-1~NurseP4-7 Under Corona Crisis Hospital Collaboration